Cargando…

Novel DNA Aptamers for Parkinson’s Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation

Parkinson’s disease (PD) is one of the most prevalent forms of synucleinopathies, and it is characterized neuropathologically by the presence of intracellular inclusions composed primarily of the protein α-synuclein (α-syn) in neurons. The previous immunotherapy targeting the α-syn in PD models with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Yuan, Qu, Jing, Xue, Fenqin, Zheng, Yan, Yang, Bo, Chang, Yongchang, Yang, Hui, Zhang, Jianliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992446/ https://www.ncbi.nlm.nih.gov/pubmed/29858057 http://dx.doi.org/10.1016/j.omtn.2018.02.011

Ejemplares similares

Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson’s Disease Model
por: Ren, Xiaoxi, et al.
Publicado: (2019)

Modulation of α-Synuclein Aggregation In Vitro by a DNA Aptamer
por: Tran, Claire H., et al.
Publicado: (2022)

Dynamics of a model for the degradation mechanism of aggregated α-synuclein in Parkinson's disease
por: Yang, Bojie, et al.
Publicado: (2023)

Models of α-synuclein aggregation in Parkinson’s disease
por: Giráldez-Pérez, Rosa María, et al.
Publicado: (2014)

Human pericytes degrade diverse α-synuclein aggregates
por: Dieriks, Birger Victor, et al.
Publicado: (2022)

Silica Nanoparticles Promote α-Synuclein Aggregation and Parkinson’s Disease Pathology
por: Yuan, Xin, et al.
Publicado: (2022)

Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
por: Lee, Jihoon, et al.
Publicado: (2023)

Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
por: Tatenhorst, Lars, et al.
Publicado: (2016)

Parkinson's disease‐linked V15A mutation facilitates α‐synuclein aggregation by reducing membrane affinity
por: Buratti, Fiamma A., et al.
Publicado: (2023)

Novel Mannitol-Based Small Molecules for Inhibiting Aggregation of α-Synuclein Amyloids in Parkinson's Disease
por: Paul, Ashim, et al.
Publicado: (2019)

Correction: Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
por: Lee, Jihoon, et al.
Publicado: (2023)

Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
por: Emin, Derya, et al.
Publicado: (2022)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

The Aggregation of Huntingtin and α-Synuclein
por: Chánez-Cárdenas, María Elena, et al.
Publicado: (2012)

Monitoring α-synuclein aggregation
por: Estaun-Panzano, Juan, et al.
Publicado: (2023)

Inducing α-synuclein compaction: a new strategy for inhibiting α-synuclein aggregation?
por: Pinheiro, Francisca, et al.
Publicado: (2019)

Sumoylation inhibits α-synuclein aggregation and toxicity
por: Krumova, Petranka, et al.
Publicado: (2011)

Catecholamines and Neurodegeneration in Parkinson’s Disease—From Diagnostic Marker to Aggregations of α-Synuclein
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models
por: Javed, Hayate, et al.
Publicado: (2019)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Anionic Nanoplastic Contaminants Promote Parkinson’s Disease-Associated α-Synuclein Aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Unveiling a Selective Mechanism for the Inhibition of α-Synuclein Aggregation by β-Synuclein
por: Leitao, Andre, et al.
Publicado: (2018)

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
por: Schulz-Schaeffer, Walter J.
Publicado: (2010)

Acceleration of α-Synuclein Aggregation by Exosomes
por: Grey, Marie, et al.
Publicado: (2015)

One ring is sufficient to inhibit α-synuclein aggregation
por: Peña-Díaz, Samuel, et al.
Publicado: (2021)

New Roles of Glycosaminoglycans in α-Synuclein Aggregation in a Cellular Model of Parkinson Disease
por: Lehri-Boufala, Sonia, et al.
Publicado: (2015)

Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease
por: Basu, Sambuddha, et al.
Publicado: (2015)

Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
por: Recasens, Ariadna, et al.
Publicado: (2018)

Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
por: Wang, Zerui, et al.
Publicado: (2020)

Inflammatory Responses to Monomeric and Aggregated α-Synuclein in Peripheral Blood of Parkinson Disease Patients
por: Piancone, Federica, et al.
Publicado: (2021)

Mechanisms of enhanced aggregation and fibril formation of Parkinson’s disease-related variants of α-synuclein
por: Ohgita, Takashi, et al.
Publicado: (2022)

Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson’s disease
por: Hideshima, Makoto, et al.
Publicado: (2022)

Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease
por: Bongianni, Matilde, et al.
Publicado: (2022)

Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease
por: Vittorio, Serena, et al.
Publicado: (2020)

Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity
por: Ysselstein, Daniel, et al.
Publicado: (2017)

Functional Impact of 14 Single Nucleotide Polymorphisms Causing Missense Mutations of Human α7 Nicotinic Receptor
por: Zhang, Qinhui, et al.
Publicado: (2015)

Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization
por: Roostaee, Alireza, et al.
Publicado: (2013)

Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients
por: Kang, Wenyan, et al.
Publicado: (2016)

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
por: George, Sonia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1vn7pfss9666m3v77pe71oflkp